期刊文献+

肠促胰素的胰腺外作用研究进展 被引量:9

Progress in the studies on extra-islet effects of incretin
原文传递
导出
摘要 肠促胰素是经食物刺激后由肠道细胞分泌人血、能够刺激胰岛素分泌的一类激素。人体中,胰升糖素样肽1(GLP-1)和糖依赖性胰岛素释放肽(GIP)发挥肠促胰素效应。本文简要介绍肠促胰素的胰腺作用,重点回顾其胰腺外生理作用,以全面评价肠促胰素类药物的临床应用前景。 Incretin is defined as an intestinal hormone released in response to nutrient ingestion, which potentiates the glucose-induced insulin response. In human body, the incretin's effect is mainly induced by two peptide hormones, glucagon-like peptide-1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide (GIP). In order to fully evaluate the clinical advantages of novel agents based on incretin, this review introduces the islet actions of incretin in brief, and mainlv focuses on the extra-islet effect of incretin.
作者 纪立农
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2011年第6期543-546,共4页 Chinese Journal of Endocrinology and Metabolism
关键词 肠促胰素 胰升糖素样肽1 糖依赖性胰岛素释放肽 糖尿病 2型 Incretin Glucagon-like peptide-1 Glucose-dependent insulinotropic polypeptide Diabetes mellitus, type 2
  • 相关文献

参考文献45

  • 1Drucker D J, Nauck MA. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase4 inhibitors in type 2 diabetes. Lancet, 2006,368, 1696-1705.
  • 2Salehi M, Aulinger BA, D'Alessio DA. Targeting β-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev, 2008,29:367-379.
  • 3Holz GG 4th, Kiihtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-I (7-37). Nature, 1993,361:362-365.
  • 4Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology, 2007,132 : 2131-2157.
  • 5Kim S J, Winter K, Nian C. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase ( PI3-K )/ protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxol and downregulation of bax expression. J Biol Chem, 2005,280:22297-22307.
  • 6Toil-Nielsen MB, Damholt MB, Madsbad S. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab, 2001,86:3717-3723.
  • 7Ding WG, Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes, 1997,46:615-621.
  • 8Knop FK. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes, 2007,56 : 1951-1959.
  • 9Nauck MA, Heimesaat MM, Hoist JJ. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide I but not of synthetic hunmn gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest, 1993,91:301-307.
  • 10Goke R, Larsen P J, Mikkelsen JD. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-I binding sites. Eur J Neurosci, 1995,7:2294-2300.

同被引文献125

  • 1秦颖.二甲双胍临床应用概述[J].继续医学教育,2012,26(3):46-48. 被引量:14
  • 2张幼怡.二甲双胍的心脏保护作用机制研究进展[J].中国医学前沿杂志(电子版),2011,3(5):21-23. 被引量:8
  • 3王燕萍,刘礼斌.GLP-1对胰岛β细胞保护作用的研究进展[J].国际内分泌代谢杂志,2007,27(2):98-100. 被引量:7
  • 4李明龙,王明雁,陈海燕.高蛋白饮食与肥胖、糖尿病[J].中国临床营养杂志,2007,15(4):237-241. 被引量:2
  • 5Elrick H, Stimmler L, Hlad C J, et al. Plasma insulin response to oral and intravenous glucose administration [J]. J Clin Endocrinol Metab,1964, 24(10): 1076-1082.
  • 6Hoist J J, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus [J]. Mol Cell Endocrinol, 2009, 297(1-2): 127-136.
  • 7Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? [J]. Diabetes, 2007, 56(8): 1951-1959.
  • 8Nauck MA, Heimesaat MM, Hoist JJ. Preserved incretin activity of glucagon-like peptide 1 but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus [J]. J Clin Invest, 1993, 91(1): 301-307.
  • 9Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review [J]. Clin Ther, 2012, 34(6): 1247-1258.
  • 10Fehse F, Trautmann M, Holst J J, et al. Exenatide augments first and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [J]. J Clin Endocrinol Metab, 2005, 90(11): 5991-5997.

引证文献9

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部